B F Gage

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation
    B F Gage
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Stroke 31:822-7. 2000
  2. ncbi Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy
    N S Ferder
    Saint Louis College of Pharmacy, St Louis, MO, USA
    J Thromb Haemost 8:95-100. 2010
  3. ncbi Integration of genetic, clinical, and INR data to refine warfarin dosing
    P Lenzini
    Department of Internal Medicine, Washington University, St Louis, Missouri, USA
    Clin Pharmacol Ther 87:572-8. 2010
  4. ncbi Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation
    B F Gage
    Division of General Medical Sciences, Washington University, St Louis, MO, USA
    Stroke 29:1083-91. 1998
  5. ncbi Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation
    B F Gage
    Division of General Medical Sciences, Washington University School of Medicine Campus, Box 8005, 660 S Euclid Ave, St Louis, MO 63110, USA
    JAMA 285:2864-70. 2001
  6. ncbi Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design
    E J Do
    Department of Internal Medicine, Washington University, St Louis, MO, USA
    Pharmacogenomics J 12:417-24. 2012
  7. ncbi A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans
    D Voora
    Department of Medicine, Washington University in St Louis, St Louis, Missouri, USA
    Clin Pharmacol Ther 87:445-51. 2010
  8. ncbi Warfarin therapy for an octogenarian who has atrial fibrillation
    B F Gage
    Division of General Medical Science, Washington University School of Medicine, Campus Box 8005, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Ann Intern Med 134:465-74. 2001
  9. ncbi Criteria for outpatient management of proximal lower extremity deep venous thrombosis
    R D Yusen
    Department of Medicine, Barnes Jewish Hospital, Washington University School of Medicine, St Louis, MO 63110, USA
    Chest 115:972-9. 1999
  10. ncbi Pharmacogenetic dose refinement prevents warfarin overdose in a patient who is highly warfarin-sensitive
    G R Grice
    J Thromb Haemost 6:207-9. 2008

Collaborators

Detail Information

Publications14

  1. ncbi Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation
    B F Gage
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Stroke 31:822-7. 2000
    ....
  2. ncbi Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy
    N S Ferder
    Saint Louis College of Pharmacy, St Louis, MO, USA
    J Thromb Haemost 8:95-100. 2010
    ..Experts have hypothesized that genotype becomes irrelevant once international normalized ratio (INR) values are available because INR response reflects warfarin sensitivity...
  3. ncbi Integration of genetic, clinical, and INR data to refine warfarin dosing
    P Lenzini
    Department of Internal Medicine, Washington University, St Louis, Missouri, USA
    Clin Pharmacol Ther 87:572-8. 2010
    ..002). After several days of therapy, a pharmacogenetic algorithm estimates the therapeutic warfarin dose more accurately than one using clinical factors and INR response alone...
  4. ncbi Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation
    B F Gage
    Division of General Medical Sciences, Washington University, St Louis, MO, USA
    Stroke 29:1083-91. 1998
    ..The preference-based strategy prescribed whichever antithrombotic therapy, warfarin or aspirin, had the greater projected quality-adjusted survival...
  5. ncbi Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation
    B F Gage
    Division of General Medical Sciences, Washington University School of Medicine Campus, Box 8005, 660 S Euclid Ave, St Louis, MO 63110, USA
    JAMA 285:2864-70. 2001
    ..Patients who have atrial fibrillation (AF) have an increased risk of stroke, but their absolute rate of stroke depends on age and comorbid conditions...
  6. ncbi Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design
    E J Do
    Department of Internal Medicine, Washington University, St Louis, MO, USA
    Pharmacogenomics J 12:417-24. 2012
    ....
  7. ncbi A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans
    D Voora
    Department of Medicine, Washington University in St Louis, St Louis, Missouri, USA
    Clin Pharmacol Ther 87:445-51. 2010
    ..14, one-sided P = 0.03). CALU rs339097 A>G is associated with higher warfarin dose requirements, independent of known genetic and nongenetic predictors of warfarin dose in African Americans...
  8. ncbi Warfarin therapy for an octogenarian who has atrial fibrillation
    B F Gage
    Division of General Medical Science, Washington University School of Medicine, Campus Box 8005, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Ann Intern Med 134:465-74. 2001
    ..Finally, when the patient develops dental pain, we review the analgesic agents that are safe to take with warfarin and explain why warfarin therapy does not have to be interrupted during a subsequent dental extraction...
  9. ncbi Criteria for outpatient management of proximal lower extremity deep venous thrombosis
    R D Yusen
    Department of Medicine, Barnes Jewish Hospital, Washington University School of Medicine, St Louis, MO 63110, USA
    Chest 115:972-9. 1999
    ..To develop and to evaluate selection criteria for outpatient management of deep venous thrombosis (DVT)...
  10. ncbi Pharmacogenetic dose refinement prevents warfarin overdose in a patient who is highly warfarin-sensitive
    G R Grice
    J Thromb Haemost 6:207-9. 2008
  11. ncbi Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
    B F Gage
    Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Pharmacol Ther 84:326-31. 2008
    ..To facilitate use of these pharmacogenetic and clinical algorithms, we developed a nonprofit website, http://www.WarfarinDosing.org...
  12. ncbi The genetics of vitamin K antagonists
    B F Gage
    Pharmacogenomics J 4:224-5. 2004
  13. ncbi Establishing and running an effective telephone-based anticoagulation service
    A D Waterman
    Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    J Vasc Nurs 19:126-32; quiz 133-4. 2001
    ....
  14. ncbi Effect of age on the incidence of venous thromboembolism after major surgery
    R H White
    Division of General Medicine, University of California, Davis, USA
    J Thromb Haemost 2:1327-33. 2004
    ..We sought to quantify the effect of age on the risk of symptomatic VTE after a spectrum of surgical procedures...